CD19 and non-Hodgkin lymphoma: In patients with NHL undergoing CD19 CART, patients who received combination cyclophosphamide with fludarabine versus cyclophosphamide alone had increased CART expansion, persistence, and objective response rates, especially CRs (50% vs 8%) (186).